文献速递妇科

子宫内膜癌的分子特征及其临床意义

Molecular Characterization and Clinical Implications of Endometrial Cancer.
PubMed 文献 · Obstet Gynecol · 2025-09-18

子宫内膜癌的分类已从传统组织学转向客观分子特征。世界卫生组织推荐将子宫内膜癌分为四个预后亚型:POLE致病性突变、错配修复缺陷、p53异常和无特异性分子谱(NSMP),其中POLE突变预后最好,p53异常和ER阴性NSMP预后最差。当前指南推荐所有患者至少检测错配修复、p53和ER,POLE检测可在特定情况下优先进行。

要点

  • 世界卫生组织推荐子宫内膜癌分子分型为POLE突变、错配修复缺陷、p53异常和NSMP四类。
  • POLE致病性突变患者预后最好,几乎无复发或死亡事件;p53异常和ER阴性NSMP预后最差。
  • 当前指南推荐所有患者检测错配修复、p53和ER,POLE检测可在特定情况下优先进行。

核心结论

  • 分子分型为子宫内膜癌提供关键框架,以实现有效、个性化、高质量诊疗并指导临床试验设计。

研究设计与样本

  • 原文为综述,检索范围未报告。

主要发现

  • POLE致病性突变患者预后最好,几乎无复发或死亡事件。
  • 强ER阳性NSMP患者预后仅次于POLE突变患者。
  • 错配修复缺陷子宫内膜癌患者预后居中。
  • p53异常和ER阴性NSMP患者预后最差。
  • 肿瘤突变负荷、人表皮生长因子受体2、L1细胞黏附分子、β-连环蛋白(CTNNB1)和淋巴血管间隙浸润等标志物可能具有预后和预测意义。

关键数值与推荐

  • 世界卫生组织建议将子宫内膜癌分为四个预后亚型:POLE致病性突变(基因测序评估)、错配修复缺陷(免疫组化或微卫星不稳定性检测)、p53异常(免疫组化或下一代测序)和无特异性分子谱(NSMP)。
  • NSMP进一步通过雌激素受体(ER)免疫组化状态进行分层。
  • 当前指南推荐所有患者至少进行错配修复、p53和ER检测,POLE检测可在特定情况下优先进行。

临床怎么用

  • 分子评估确保诊断一致性,并提供预后信息和预测数据以指导适当管理。
  • 当前指南推荐所有患者检测错配修复、p53和ER,POLE检测可在特定情况下优先进行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The classification of endometrial cancer (EC) has diverged from traditional histologic features based on microscopic appearance to objective molecular characterization. Molecular characterization of EC is pivotal to inform prognosis and to guide therapeutic recommendations. First described by the Cancer Genome Atlas, molecular profiling was later revised by the Proactive Molecular Risk Classifier for Endometrial Cancer and TransPORTEC algorithms to create clinically applicable and relatively easy-to-implement molecular classification systems. Since 2020, the World Health Organization recommended molecular classification of EC into four distinct prognostic subtypes: ECs with polymerase ε (POLE) pathogenic mutations assessed by gene sequencing, mismatch repair deficiency determined by immunohistochemistry or microsatellite instability assay, and p53 abnormalities determined by immunohistochemistry or next-generation sequencing. The final molecular subtype without any of these defining features is called "no specific molecular profile" (NSMP). This is further stratified by estrogen receptor (ER) immunohistochemistry status. Patients with cancers identified as POLE pathogenic mutations have the best prognosis with almost no recurrence or death events, followed by those with strong ER-positive NSMP cancers. Mismatch repair deficiency ECs have intermediate prognosis, whereas p53 abnormalities and ER-negative NSMP have the worst prognosis. Other molecular and pathologic biomarkers of interest include tumor mutational burden, human epidermal growth factor receptor 2, L1 cell adhesion molecule, β-catenin ( CTNNB1 ), and lymph vascular space invasion, which may have prognostic and predictive implications. The current guidelines will continue to evolve; however, at minimum, it is recommended that all patients undergo testing for mismatch repair, p53, and ER, and POLE testing may be prioritized in select circumstances. Molecular classification provides the critical framework to deliver effective, personalized, high-quality care and informs clinical trial design. Molecular assessment ensures consistent diagnosis and provides prognostic information and predictive data to guide appropriate management.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Secord AA, Powell MA, McAlpine J, et al. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025. PMID: 40966692. doi:10.1097/AOG.0000000000006080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。